LabGenius is the first biopharmaceutical company to develop next-generation protein therapeutics using a machine learning-driven evolution engine (EVA™). Our protein engineering platform integrates several bleeding edge technologies from the fields of machine learning, synthetic biology, and robotics.
LabGenius develops next-generation protein therapeutics using a machine learning-driven evolution engine (EVA). We use robotic automation, synthetic biology, and advanced machine learning to explore protein fitness landscapes and improve multiple drug properties simultaneously. We are a privately-owned company, backed by top-tier venture capital funds, currently based in London
Total Funding: $28,700,000
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2012
